Jason M. Aryeh's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 2,034 Common Stock done at an average price of $69.5 . Disclosure was reported to the exchange on Dec. 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 69.51 per share. | 08 Dec 2025 | 2,034 | 71,323 (0%) | 0% | 69.5 | 141,383 | Common Stock |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 2,034 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Sale of securities on an exchange or to another person at price $ 170.96 per share. | 23 Sep 2025 | 4,628 | 70,243 (0%) | 0% | 171.0 | 791,223 | Common Stock |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Sale of securities on an exchange or to another person at price $ 170.41 per share. | 23 Sep 2025 | 4,418 | 74,871 (0%) | 0% | 170.4 | 752,850 | Common Stock |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Sale of securities on an exchange or to another person at price $ 171.92 per share. | 23 Sep 2025 | 954 | 69,289 (0%) | 0% | 171.9 | 164,015 | Common Stock |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Purchase of securities on an exchange or from another person at price $ 2.45 per share. | 19 Sep 2025 | 1,000 | 108,482 | - | 2.5 | 2,450 | Common Stock, par value $0.0001 per share |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 15,000 | 107,482 | - | 0 | Common Stock, par value $0.0001 per share ("Common Stock") | |
| Lifecore Biomedical Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 19,506 | 44,060 (0%) | 0% | - | Common Stock | |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 36,797 | 36,797 | - | - | Stock Option (Right to Buy) | |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 12,422 | 92,482 | - | 0 | Common Stock, par value $0.0001 per share ("Common Stock") | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 5,783 | 5,783 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 1,209 | 79,289 (0%) | 0% | 0 | Common Stock | |
| Anebulo Pharma Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Anebulo Pharma Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2025 | 4,964 | 4,964 | - | - | Stock Option (right to buy) | |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 27 Dec 2024 | 11,700 | 80,060 | - | 4.3 | 50,310 | Common Stock, par value $0.0001 per share ("Common Stock") |
| Orchestra BioMed Holdings Inc | M. Jason Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2024 | 11,700 | 6,900 | - | - | Stock Option (Right to Buy) | |
| Lifecore Biomedical Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 24,554 | 24,554 (0%) | 0% | - | Common Stock | |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 17,068 | 17,068 | - | - | Stock Option (Right to Buy) | |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 5,376 | 68,360 | - | 0 | Common Stock, par value $0.0001 per share ("Common Stock") | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 5,444 | 5,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 1,252 | 78,080 (0%) | 0% | 0 | Common Stock | |
| Anebulo Pharma Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 41,667 | 41,667 | - | - | Stock Option (right to buy) | |
| Anebulo Pharma Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 2,482 | 2,482 | - | - | Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.30 per share. | 30 Apr 2024 | 2,406 | 76,828 (0%) | 0% | 52.3 | 125,834 | Common Stock |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 2,406 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2024 | 2,893 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 39.35 per share. | 05 Mar 2024 | 2,893 | 74,422 (0%) | 0% | 39.4 | 113,840 | Common Stock |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 5,461 | 5,461 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2023 | 1,142 | 71,529 (0%) | 0% | 0 | Common Stock | |
| Orchestra BioMed Holdings Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 23,250 | 23,250 | - | - | Nonstatutory Stock Option (Right to Buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 4,484 | 4,484 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,340 | 4,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 1,004 | 69,668 (0%) | 0% | 0 | Common Stock | |
| Anebulo Pharma Inc | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 30,425 | 30,425 | - | - | Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 3,269 | 3,269 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Jason M. Aryeh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 630 | 68,664 (0%) | 0% | 0 | Common Stock |